Urology - Global Oncology Academy

1-16 of 34

Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Project Oncology®
Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
- Brian P. McDonough, MD, FAAFP
- Matthew Galsky, MD
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
- Wayne Kuang, MD
- William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
- William Oh, MD
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
Clinician's Roundtable
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
- Ihtisham Ahmad
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CE
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
0.50 credits
- Elizabeth R. Plimack, MD, MS, FASCO
- Shilpa Gupta, MD
0.50 credits
MinuteCE®
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
0.50 credits 3 episodes
- Elizabeth R. Plimack, MD, MS, FASCO
- Lillibeth Velasco, MSN, RN
0.50 credits 3 episodes
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
1.25 credits 10 episodes
- Ignacio Duran, MD
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 credits 10 episodes
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
1.25 program credits

Prev
1
2
3
Next

1/3